Talimogene laherparepvec: overview, combination therapy and current practices
نویسندگان
چکیده
منابع مشابه
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S. oncology community has been slow, and so far has been largely limited to specialized cancer centers. Limiting factors include the ...
متن کاملA practical guide to the handling and administration of talimogene laherparepvec in Europe
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically m...
متن کاملAdministration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
PURPOSE/OBJECTIVES To describe the administration and handling requirements of oncolytic viruses in the context of talimogene laherparepvec (Imlygic™), a first-in-class oncolytic immunotherapy. . DATA SOURCES Study procedures employed in clinical trials, in particular the OPTiM study. . DATA SYNTHESIS Evaluation of nursing considerations for administration of talimogene laherparepvec. . C...
متن کاملSpotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another therapeutic option to the growing list of effective therapies for melanoma. Though the Phase III OPTiM trial has demonstrated its efficac...
متن کاملTalimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
MCC: Merkel cell carcinoma MCPyV: Merkel cell polyomavirus PET/CT: position emission tomography/ computed tomography PD: programmed death TVEC: talimogene laherparepvec UV: ultraviolet INTRODUCTION Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy with a propensity for locoregional recurrence and hematogenous spread. MCC typically presents in elderly patients with fair comp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Melanoma Management
سال: 2016
ISSN: 2045-0885,2045-0893
DOI: 10.2217/mmt-2016-0021